Selected abstracts

15329413

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.
William Pao, Vincent Miller, Maureen Zakowski, Jennifer Doherty, Katerina Politi, Inderpal Sarkaria, Bhuvanesh Singh, Robert Heelan, Valerie Rusch, Lucinda Fulton, Elaine Mardis, Doris Kupfer, Richard ...
(Program in Cancer Biology and Genetics and Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA. paow@mskcc.org)
Proc. Natl. Acad. Sci. U.S.A.

egfr gene sensitivity cancers exon point_mutations codon exon tumors had alterations mutations tumors tumors had tumors tumors adenocarcinomas patients cigarettes smokers adenocarcinomas never_smokers tumors had mutations cancers current_smokers cells egfr wild-type protein mutant levels phosphorylation exon mutant concentrations drug adenocarcinomas never_smokers cancers mutations egfr gefitinib erlotinib sensitivity

16014882

Erlotinib in previously treated non-small-cell lung cancer.
Frances A Shepherd, José Rodrigues Pereira, Tudor Ciuleanu, Eng Huat Tan, Vera Hirsh, Sumitra Thongprasert, Daniel Campos, Savitree Maoleekoonpiroj, Michael Smylie, Renato Martins, Maximiliano van Koo ...
(Department of Medical Oncology, University Health Network, Princess Margaret Hospital Site, University of Toronto, Canada.)
N. Engl. J. Med.

erlotinib after failure second-line_chemotherapy patients had patients response chemotherapy therapy ratio oral erlotinib dose placebo patients randomization years percent had percent had platinum-based_chemotherapy percent erlotinib group percent response months months months months adjusted months months erlotinib percent patients erlotinib erlotinib survival patients after second-line_chemotherapy

15728811

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.
Susumu Kobayashi, Titus J Boggon, Tajhal Dayaram, Pasi A Jänne, Olivier Kocher, Matthew Meyerson, Bruce E Johnson, Michael J Eck, Daniel G Tenen, Balázs Halmos
(Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA.)
N. Engl. J. Med.

mutations egfr gene specimens patients response egfr inhibitors inhibitors patients relapse egfr-mutant relapse after years treatment gefitinib dna egfr gene tumor relapse position egfr mutation gefitinib resistance